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Abstract
Diabetic nephropathy (DN) and diabetic retinopathy (DR) are two serious and 
long-standing microvascular complications of type 2 diabetes mellitus (T2DM) 
whose burden is increasing worldwide due to increasing burden of T2DM. Several 
factors which may predispose to the development of DN and DR are persistent 
hyperglycemia and its consequences such as formation of advanced glycation end 
products (AGEs), activation of hexosamine pathway, polyol pathway, uncontrolled 
blood pressure, increased oxidative stress, age, family history of kidney disease or 
hypertension, ethnic background etc. However, the pathophysiological mechanisms 
of these complications are complicated and not completely understood yet. Hence 
it is the demand to discover newer approaches to treat these devastating complica-
tions completely. Recently, various epigenetic modifications, which are the trans-
missible alterations in the expressions of a gene, are being studied to understand the 
pathophysiology of diabetic vascular complications. Metabolic and environmental 
factors may lead to dysregulated epigenetic mechanisms which might further 
affect the chromatin structure and related expressions of a gene, which may lead 
to diabetes-associated complications. Therefore, it is the need to explore its role in 
vascular complications in the current scenario. In this chapter, various epigenetic 
studies with regard to DN and DR, epigenome-wide association studies (EWAS) 
approach, and starting clinical material for such studies have been discussed. We 
have also summarized the better understanding of epigenetic alterations and their 
role in microvascular complications of diabetes through this chapter. The better 
understanding of epigenetic mechanisms and their role in diabetic microvascular 
complications could be used in clinical management of DN as well as DR or could 
be helpful to improve the available therapies for these complications.
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1. Introduction
Diabetes is a chronic metabolic disorder in which blood glucose levels upsurge 
more than normal. Type 2 diabetes mellitus (T2DM) contributes to the majority 
of diabetes cases accounting for more than 90% of them. An imbalance of insulin 
supply and demand results in type 2 diabetes [1]. Decrease in insulin sensitivity 
accompanied by deficiency of insulin are the two primary pathogenetic defects 
underlying type 2 diabetes and together explain 85–90% of diabetes [2]. Long term 
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diabetes instigates vascular diseases affecting almost all blood vessels of the body, 
which further results in increased morbidity and mortality in diabetic populations. 
Among well-known risk factors of diabetes, non-changeable factors include genet-
ics, age and ethnicity while others are changeable, for example physical activity, 
adiposity, environmental exposures and diet, via combination of treatment at both 
individual as well as population level [3]. Type 2 diabetes is frequently seen in older 
adults, but now-a-days, may be, as a result of increasing physical inactivity, obesity 
and/or the absence of healthy diet it is also being seen increasingly among children, 
teenagers and younger adults. Diabetes is globally affecting 425 million people or 
8.8% of adult population. By 2045, diabetes is projected to affect about 629 million 
of adult population in the world [3].
India, now-a-days, is becoming the diabetes capital of the world with estimated 
prevalence of diabetes as 7.3% and that of pre-diabetes as 10.3% [4]. In the current 
report (2017), 72.9 million Indians were suffering from diabetes and this is expected 
to rise to 134.3 million by the year 2045 [3]. Prolonged hyperglycemia is the fore-
most cause of kidney disease, cardiovascular disorders, retinopathy and neuropathy 
[5], which are the main vascular complications of diabetes.
2. Diabetes mellitus-associated vascular complications
Hyperglycemia triggers damage to the vasculature and thus, leads to the fail-
ure of various organs including kidney, heart, retina of eyes and nerves; usually 
develop after many years of diabetes. This gives rise to the development of vascular 
complications which are categorized into micro- and macrovascular complications. 
Microvascular disease or microangiopathy is actually the thickening of walls of 
small blood vessels so that they bleed and leakage of protein occurs. This narrow-
ing of blood vessels results in decreased blood flow and impairment of oxygen 
flow throughout the body which leads to the damage of tissues or organs that are 
extremely sensitive to oxygen levels i.e., kidney cells, nerve cells and retina. On the 
other hand, macrovascular disease or macroangiopathy is the disease of large blood 
vessels due to clot formations that further results in the decreased blood flow all 
through the body. This may cause heart diseases, peripheral vascular diseases or 
stroke. Both micro- and macrovascular complications are the result of hypergly-
cemia and it seems that they both may be interconnected but who precedes whom 
or whether they progress together, it is not clear. Complications of T2DM keep on 
increasing due to increasing burden of diabetes, thus deteriorating the quality of 
human life. Smoking, age factor, increased weight, lack of physical activity and 
high-fat diet are the common risk factors to diabetes complications. Now-a-days 
diabetic kidney disease (DKD) or DN and diabetic retinopathy (DR) are among 
the most frequent complications of diabetes. Improved and maintained glycemic 
control may reduce risk of some of the diabetic complications, but it is not the only 
factor which, if under control, may reduce the progression of all vascular complica-
tions. In this segment, we have elaborated two major microvascular complications 
of diabetes, i.e., DN and DR.
2.1 Diabetic nephropathy
Diabetic nephropathy is the major microvascular complication of diabetes 
affecting 20–30% of patients with type 2 diabetes mellitus [6], which weaken the 
quality of life leading to increased morbidity and mortality. Symptoms of DN are 
less evident in the early years of diabetes, usually develops after many years of 
diabetes. In India approximately 48% cases of CKD are caused by diabetes [7]. 
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DN is defined as a clinical syndrome characterized by persistent proteinuria, a 
moderate deterioration of eGFR and an increasing arterial blood pressure [8]. 
Being the foremost cause of end-stage renal disease (ESRD), it results in consider-
able morbidity and mortality and incurs massive burden of cost on patient and 
the society as well. Pathways, specifically renin-angiotensin-aldosterone system 
(RAAS), have been known to play a central role in the development and progression 
of nephropathy which eventually triggers numerous inflammatory factors directing 
to the development of fibrosis in the kidney, hypertension/hyperfilteration in the 
glomerulus and increased permeability to macromolecules leading to proteinuria 
[9]. It has been seen that some patients with good glycemic control may develop 
DN at later stages and patients with poor glycemic control may not always develop 
DN. This may partly be due to genetic predisposition among various ethnic popula-
tions. Presence of diabetic nephropathy within families and the large differences 
in its incidence among diabetic populations with different ethnicity suggests the 
contribution of several genetic and epigenetic factors in the development and 
progression of DN. Till date several candidate genes, that are susceptible to DN, 
have been recognized with the advancements of molecular techniques via linkage 
studies, GWAS or candidate gene studies. The important candidate genes includes 
ADIPOQ [10] and ACACβ [11] from lipid metabolism, GCKR [12] and TCF7L2 [13] 
from glucose metabolism, transforming growth factor-β1 (TGF-β1) involved in 
inflammation [14], genes associated with angiogenesis i.e., VEGF-A [15] and RAAS 
genes i.e., ACE [16] and AGTR1 [17], and recently SLC12A3 [18] whose various 
polymorphisms are reported to be associated with DN. Genes involved in RAAS 
have been most extensively investigated in the context of DN. Among RAAS genes, 
angiotensin converting enzyme (ACE) gene is found to be strongly correlated with 
DN. For this reason, ACE inhibitors and angiotensin receptor blockers (ARBs) 
are the first line of drugs for the treatment of diabetic nephropathy that aims to 
reduce proteinuria. Though these drugs have shown to reverse the progression of 
albuminuria from macroalbuminuria or microalbuminuria to normoalbuminuria 
[19], thereby slows down the progression of disease, but are not able to provide a 
stable renoprotective effect. The response of DN patients to ACE inhibitors or ARBs 
alone or in combination is also not uniform despite several studies. Moreover, there 
are some limitations regarding their usage based on particular patient to be treated. 
Hence, these drugs along with strict glycemic control contribute to some degree of 
renoprotection, but not complete. Therefore, it is the urge to discover new path-
ways leading to the development of more specific therapies/treatments to help DN 
patients and improving their life.
2.2 Diabetic retinopathy
Diabetic retinopathy is a medical condition where damage to retina, as a result 
of high glucose, occurs. It is the most frequent cause of blindness in patients with 
diabetes. Patients with DR usually does not develop any major symptoms at an early 
stage but during later stages physiological and metabolic abnormalities can appear 
leading to blindness, if left untreated. The risk factors associated with DR includes 
high blood glucose [20], duration and type of diabetes [21], high B.P. [22] and, 
lipids [23]. Presently it is being diagnosed with the identification of microvascular 
lesions in the retina. It has been differentiated clinically in 2 categories on the 
basis of ophthalmic observation: proliferative DR (PDR), the advance stage and; 
non-proliferative DR (NPDR), the early stage. NPDR can be identified by fundus 
where hard exudates, microaneurysms or hemorrhages are seen. NPDR is further 
categorized into mild, moderate and severe NPDR. On the other hand, detection 
of retinal neovascularization confirms PDR. The risk of progression of DR can 
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be reduced by early detection, but it is difficult to achieve as there is little or no 
symptoms at early stages. Several molecular mechanisms are thought to involve 
in the development and progression of DR including polyol pathway, enhanced 
expression of vascular endothelial growth factor (VEGF), production of advance 
glycation end products (AGEs), activation of RAAS, hemodynamic alterations, etc. 
Current treatment involves conventional laser therapy and anti-VEGF or other anti-
angiogenic, anti-inflammatory, non-steroidal anti-inflammatory drugs (NSAIDs) 
treatment. Despite this, reading is also difficult in patients with severe retina loss. 
Some treatments are precise but they are associated with high cost or side effects. 
Hence, the discovery of fundamental molecular mechanisms involved is required 
for the development of more specific interventions. Among genetic predisposition 
to the disease, several candidate genes have been identified in the past few decades 
with contradictory findings, although few genes have been found to be associated 
with DR in mostly studies. Among them, aldose reductase (AKR1B1) is important 
enzyme in polyol pathway. Activation of this pathway and AKR1B1 polymorphisms 
are incriminated in the pathogenesis of DR [24]. VEGF is another the most impor-
tant growth factor activated by hyperglycemia and implicated in the development 
and progression of DR [25]. Various polymorphisms of VEGF were found to be 
associated with DR with conflicting results [24]. ACE I/D polymorphism was found 
to be associated with PDR in a meta-analysis [26]. Receptor for advance glycation 
end products (RAGE) gene polymorphisms is also reported to be associated with 
DR in Indian population [27].
The pathophysiology of complications of diabetes is very complex as depicted in 
Figure 1.
Figure 1. 
Signaling pathways facilitating the pathogenesis of microvascular complications of diabetes mellitus.
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Diabetes-induced hyperglycemia promotes various growth factors which play influ-
ential roles in the progression of diabetic complications. These factors act by binding 
to their specific receptors to initiate multiple downstream signaling cascades involved. 
Subsequently, these signaling pathways trigger transcription factors and promote their 
crosstalk with epigenetic mechanisms that lead to diabetic microvascular complications. 
Transcription factors also interact with epigenetic factors that further participate in 
metabolic memory. AT1R, Angiotensin II type 1 receptor; AGEs, Advance glycation end 
products; TGF-β, Transforming growth factor-β1; ROS, Reactive oxygen species; NO, 
Nitric oxide; Akt, Serine/threonine-specific protein kinase; PKC, Protein kinase C; 
MAPK, Mitogen-activated protein kinase; NF-κB, Nuclear factor-κB; USFs, Upstream 
stimulatory factors.
Several genetic factors and gene polymorphisms have been extensively discov-
ered, studied and implicated in DN as well as DR, but no report is able to provide 
strong evidence regarding uneven response to available treatment. No drug or 
treatment is able to provide a stable and long-term protective effect against these 
complications.
In past few years, a lot of interest has been generated in gene–environment 
interactions as they seem to be involved in the pathophysiology of diabetes mel-
litus. Recently, epigenetic mechanisms have been linked to various complications of 
diabetes, as altered gene expressions are the results of several post-transcriptional 
modifications (PTMs) of chromatin. Accomplishing complete control of blood 
glucose is also not sufficient to stop or retard the development and progression of 
diabetes complications; this proposes the involvement of initial glycemic ‘metabolic 
memory’ in various complications of diabetes. So, how epigenetic modifications 
play the role in diabetic vascular complications is still not completely understood, 
therefore, we have described the understanding about epigenetic mechanisms and 
their role in the pathophysiology of diabetic microvascular complications.
3. Epigenetics-an addition to current treatment strategy
In mammalian cells, expression of a gene is known to be controlled by genetic 
as well as epigenetic mechanisms. In the recent times, epigenetic mechanisms have 
been shown to play substantial roles in the development and progression of diabetes 
and its microvascular complications. In this section, epigenetic mechanisms have 
been elaborated in the complications of diabetes.
Epigenetic mechanisms are deprived of any modification in the principal DNA 
structure which involves vibrant switching within ‘active’ (euchromatin) and 
‘inactive’ (heterochromatin) positions of chromatin; that determined ‘gene activa-
tion’ and ‘gene repression’ states and thus biological outcomes [28]. Fundamentally, 
any change, in the expression of a gene without variation in its nucleotide (DNA) 
sequence, unlike genetic variations, is known as epigenetic variation. Subsequently, 
epigenetic studies in diabetic complications may help us to understand the role of 
epigenetic mechanisms in the alteration of expressions of genes involved in various 
complications. Hypermethylation at CpG Island in promoter region of a gene is 
likely to silence its expressions. In contrast, when CpG turns out to be hypometh-
ylated, reverse can takes place [29]. At first, ‘epigenetics’ term was described by 
Waddington as ‘the casual interaction between genes and their products which 
bring the phenotype into being’ [30]. Epigenetic mechanisms maintains the 
structure of chromatin to confer transcription memory important for the faithful 
transmission of gene expression pattern across multiple cell divisions even in the 
absence of signals that initiated them [31]. Such a control of gene expression by the 
epigenetic modifications elucidates the mechanisms which triggers our cells with 
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the same DNA to differentiate into numerous cell types with various phenotypes 
[32, 33]. That’s why phenotype of a person is not only decided by its genome but by 
its epigenome too.
3.1 Factors associated with epigenetic mechanisms
The suggested mechanism behind altered expression of a gene was the activation 
of an intracellular signal by environmental factors, which sequentially specifies 
the accurate chromatin position for epigenetic alterations [34, 35]. Certain envi-
ronmental aspects takes place during the course of formation and development 
of embryo (such as maternal diet and intrauterine nutrition) and such an initial 
development could influence health and disease conditions even at later stages 
[36]. Additionally, several other environmental exposures accelerate alterations 
in epigenetic mechanisms, such as heavy metal exposure, smoking, revelation of 
pesticides, even insufficiencies of nutrients (such as folate and methionine) [37]. 
Moreover these mechanisms are also appeared to be altered by age and obesity 
which may possibly cause type 2 DM [38].
3.2 Epigenetic mechanisms in diabetes mellitus and its complications
In past few years, environment has shown a significant role in activating diabe-
tes, although diabetes has a trend to run in family due to intense genetic component. 
Obesity, older age and sluggish routine with absence of physical doings are the 
pronounced risk factors for getting hyperglycemia. Diabetes may cause altered 
epigenetic mechanisms which can direct diabetes-associated complications such as 
diabetic nephropathy, by altered expression of genes in target cells as depicted in 
Figure 2 [39].
Diabetes mellitus results in the activation of several signaling pathways following 
activation of alterations in DNA and histone proteins and transcription factors includ-
ing NF-κB. These mechanisms via chromatin remodeling resulted in regulated target 
genes expression in targeted tissues along with activation of several ncRNAs including 
miRNAs, lncRNAs and circRNAs. Such post transcriptional alterations in target tissues 
resulted in specific key pathological changes in specific tissues and promote the develop-
ment of specific vascular complication of diabetes. Even after blood glucose control, 
synchronized crosstalk between various transcription factors and altered epigenetic 
mechanisms contribute to the metabolic memory and increased expression of ncRNAs 
that is embroiled in risk of development of microvascular complication of diabetes.
High glucose can also stimulate abnormalities in DNA at key genes which are 
well-known to be involved in endothelial dysfunction as evident by sequencing 
studies in endothelial cells [40]. Augmented DNA methylation at the promoter 
region of peroxisome proliferator activated receptor gamma coactivator-1 
alpha (PPARGC1A) was reported to be associated with decreased expression of 
PPARGC1A in pancreatic islets [41]. Tewari et al. [42] have demonstrated the 
decreased transcriptional activity owing to decreased binding of mitochondrial 
DNA (mtDNA) to DNA polymerase as a result of hypermethylation at regulatory 
region of DNA polymerase. Global DNA hypomethylation and thereby, anomalous 
gene expression due to hyperglycemia was observed in the animal model of dia-
betes, which was further correlated with inadequate wound healing process [43]. 
Glucose-induced insulin secretion was shown to be influenced by hyper-acetylation 
of H4 (histone) at promoter region of insulin gene [38]. Hyperglycemic environ-
ment exposure to endothelial cells showed the increased expression of p65 subunit 
of NF-κB along with other inflammatory genes that correspond with increased 
H3K4me1 alterations on promoter region of p65 subunit [44].
7
Diabetes Microvascular Complications: An Overview of Epigenetic Modifications
DOI: http://dx.doi.org/10.5772/intechopen.94642
Hyperglycemia has also shown to alter micro RNA (miRNA), a mechanism of 
epigenetic modifications, which is also implicated in complications of diabetes. 
The alteration in miRNA-133a has been reported in cardiomyocyte hypertrophy in 
diabetes patients [45]. miRNA-320 upregulation was also observed in myocardial 
microvascular endothelial cells in rat model with type 2 diabetes [46]. The elemen-
tary epigenetic modifications viz., (a) methylation of promoter sites in DNA, (b) 
modifications in histone proteins and, (c) non-coding RNAs facilitated pathways, 
as illustrated in Figure 3, known to modify the expressions of a gene are described 
as below:
DNA in chromosomes is packed round the histones to form nucleosomes. Unwrapping 
and accessibility of nucleosomes is regulated by alterations in histone proteins. DNA 
methylation involves addition or removal of methyl groups to cytosine residues in CpG 
islands via DNA methylating enzymes (DNMT) or DNA demethylases, thus, prevent-
ing the binding of transcription factors and suppressing respective gene expression. 
Histone modifications include acetylation, methylation and phosphorylation. HATs/
HDACs regulates the acetylation and deacetylation of histone tails, whereas histone 
methylation is regulated by HMTs/HDMs. Alterations in histone tail coupled with DNA 
methylation and control the chromatin accessibility or inaccessibility, hence, regulating 
the expression of various genes. ncRNAs can be act as housekeeping molecules or regula-
tory molecules. miRNAs act as regulatory molecules among epigenetic mechanisms and 
are most widely studied mechanism regulating gene expressions at post-transcriptional 
level. This dynamic condition of chromatin is exposed to modifications by external 
Figure 2. 
Pathways preceding the development of microvascular complications of diabetes.
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stimuli via regulation of miRNAs, thus directing several pathophysiological outcomes. 
DNMTs, DNA methyl transferases; HATs, Histone acetyl transferases; HDACs, Histone 
deacetylases; HMTs, Histone methyl transferases; HDMs, Histone demethylases; ncRNAs, 
non-coding RNAs, miRNAs, micro RNAs.
a. Methylation of DNA
It is the renowned epigenetic modification that is well studied in cancer, and lot 
of interest has been generated in DNA methylation in the framework of diabetes 
and its related complications. In detail, DNA undergoes methylation at 5th posi-
tion of CpG dinucleotides and form 5-methylcytosine, which is a post-replicative 
mechanism. DNA methylation is extremely dynamic process in the progress of 
a disease, which tends to alter related gene expressions. These alterations can be 
reversed by external stimuli. Commonly repression of a gene takes place due to 
addition of methyl groups at promoter region on DNA, while methylation at gene 
bodies may regulate their transcription during elongation and also during alterna-
tive splicing [31].
DNA methyl transferases (DNMTs) are known to catalyze DNA methylation 
reaction which, in freshly synthesized DNA, methylates CpG dinucleotides. Hence, 
to sustain DNA methylation in proliferating cells, DNMTs are vital. Throughout the 
embryonic development, for de novo methylation, presence of DNMT-3a and -3b 
enzymes is obligatory [47]. The molecular effects of DNA methylation were inter-
ceded by a group of methyl binding domain (MBD) proteins. Out of these, merely 
MBD2 alone is identifiable for methyl-CpG positions, which guides the interaction 
of methylated DNA to a multifaceted complex encompassing nucleosome remodel-
ing and histone deacetylases (HDACs) bustles, thereby conducting silencing of a 
gene [48]. DNA methylation is commonly studied by various methods including 
methylation specific PCR (MS-PCR), methylation sensitive high resolution melt 
Figure 3. 
Framework of inheritable epigenetic modifications.
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curve (MS-HRM), immunoprecipitation or sequencing approaches. Advantage of 
MS-HRM is that it offers a low-cost and rapid method for the detection of even low 
levels of methylation at gene promoters.
Earlier exposure of target cells to high glucose can result in a ‘metabolic memory’ 
which results in persistence of its detrimental effects long after glucose stabiliza-
tion. Diabetes-induced altered epigenetic mechanisms, resulting in modified gene 
expression in target cells can lead to diabetes-associated complications, such as dia-
betic nephropathy [39]. In the pathogenesis of DN and ESRD, DNAme (DNA meth-
ylation) has been explored by several studies via studying differentially methylated 
genes related to DN [31, 49, 50]. In a genome-wide methylation analysis (GWAS), 
significant alterations in DNA methylation in DN patients as compared to control 
were reported at 19 CpG sites that were found to be associated with the risk of DN. 
They also correlated the degree of methylation with time to development of DN 
[50]. In DNA isolated from the saliva of type 2 diabetic patients with end-stage kid-
ney disease (ESRD), differentially site-specific methylation of DNA was recorded 
at 187 gene targets in comparison to those without ESRD [49]. DN patients have 
altered DNA methylation at important key gene promoters in comparison to those 
without DN [50]. However, studies in DN animal models or in renal cells under 
hyperglycemic conditions were not competent to show any significant changes in 
DNA methylation patterns [51]. In patients having type 2 diabetes with diabetic 
nephropathy, global DNA methylation variations were also observed to be associated 
with albuminuria in a recent study [52]. Noteworthy alterations in histone and DNA 
methylation patterns were observed to be present in peripheral blood mononuclear 
cells (PBMCs) of patients with membranous nephropathy [53]. Genome-wide DNA 
methylation study also depicted modifications in differential DNA methylation 
profiles among type 1 diabetes patients with or without nephropathy, where degree 
of methylation is linked with time towards the progression of DN [50].
It has been demonstrated that the promoter of human ACE gene, the most 
important and widely studied gene in pathophysiology of DN, harbor CpG islands. 
ACE transcription and expression levels were also observed to be influenced by 
methylation in its promoter region both in vivo and in vitro [54]. The magnitude of 
epigenetic alterations, particularly DNA methylation, has been shown to correlate 
with ACE activity levels [54, 55]. These studies demonstrated an increase in ACE 
activity with hypomethylation of ACE gene promoter. Also, a relation between epi-
genetics of ACE gene and I/D polymorphism has been suggested, where decreased 
DNA methylation in 3 CpG sites of ACE gene was observed in low birth weight 
(LBW) children with DD genotype although this has not been reported directly 
in DN patients [55]. Global DNA methylation variations were also observed to be 
associated with albuminuria in a recent study [52]. Additionally alterations in DNA 
methylation of ACE promoter are suggested to be a fundamental cause of major 
depression (MD) and a shared pathogenic factor for bi-directional connection 
between MD and cardiovascular disorders [56].
Apart from the importance of DNA methylation in DN, their role in DR is not 
clear, however, DNA methylation has been shown to control the expressions of 
many genes associated with retinal homeostasis. Previous studies have shown the 
link of DR development and DNA methylation, which indicates that DR may be 
associated with epigenetic alterations. In this connection, a GWAS between PDR 
and healthy controls was conducted in PBMC’S sample and out of 349 identified 
methylated sites, only 17 genes were observed to be hypermethylated [57]. They 
assumed that PBMCs could be used as a predictor for diabetic retinopathy. Another 
study evaluated global DNA methylation levels in blood leukocytes in persons with 
and without retinopathy [58]. They found a significantly higher global methylation 
levels in patients with DR than those without DR. These changes were seen to be 
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progressive from non-DR stage to NPDR and eventually to PDR and were indepen-
dent of hyperglycemia, dyslipidemia, diabetes duration and person’s blood pressure. 
Binding of polymerase gamma 1 (POLG1) to mtDNA (mitochondrial DNA) also 
results in compromised transcriptional activity as a result of hypermethylation at 
promoter region of DNA polymerase gamma 1 (POLG1) in the hyperglycemic envi-
ronment [42]. This study was conducted in rat model of diabetes which showed that 
the mitochondrial damage in retina of diabetic rats could be diminished/controlled 
by maintaining stable glycemic control for longer time periods or therapy that 
targets directly DNA methylation. However, it does not benefit DNA methylation 
machinery by the reversal of hyper-glycemic environment for shorter duration [59]. 
In people with diabetes mellitus, it has been seen that activity of Dnmt1 enzyme 
was elevated in retinal and its capillary cells. However, this was not observed with 
Dnmt-3a or Dnmt-3b [60, 61]. Similar differential DNA methylation patterns were 
also observed in persons with PDR [57].
b. Histone modifications:
It is the interesting and emerging mechanism that exhibits the addition of 
methyl groups at histones related to a gene. As DNA is structured into chromosomes 
in eukaryotic cells, it is tightly wrapped onto series of nucleosomes (the basic unit 
of chromatin), which are the octamer complexes of small core (a H3-H4 tetramer 
and two H2A-H2B dimers) linked by linker histone proteins (H1) [62]. These his-
tones are involved in post-translational modifications (PTMs) which may regulate 
gene expressions. The gene activation and repression are determined by dynamic 
chromatin structure that directly depends upon these PTMs, as they will allow 
transformation of inactive or repressive chromatin to euchromatin, the active con-
dition of chromatin. These modifications, like DNA methylation, are able to regu-
late the gene expression without any change in its DNA sequence. Hence, histone 
tails can be acetylated, methylated, or phosphorylated. Histones with methylated 
(Kme) or acetylated (Kac) lysine residues, mostly at amino terminal tails, have been 
identified. Generally, these modifications are correlated with either gene activation 
or repression. Like, on one hand, histone lysine acetylation (H3K9ac, H3K14ac and 
H4K5ac) is generally associated with gene activation that opens the chromatin for 
the binding of transcription machinery [63]. Histone acetylation is tightly con-
trolled by the equilibrium between acetylation (HATs) and deacetylation (HDACs) 
enzymes that add or deletes acetyl group. On the other hand, methylation on lysine 
or arginine residues can be correlated with both, gene activation or gene repression, 
depending on the residue to be modified. For example, mono- or tri-methylation 
of Histone 3 at lysine 4 residue (H3K4me, H3K4me3), H3K79me2 [64] and at lysine 
36 residue (H3K36me) facilitated by lysine methyl transferases (KMTs) such as 
SET1/7/9 are associated with gene activation [63]. Although, mono-methylation 
of histone 3 at lysine residue 9 (H3K9me) mediated by suppressor of variegation 
3–9 homolog 1 (SUV39H1) is correlated with gene activation whilst, its trimeth-
ylation (H3K9me3) is linked with gene repression [65]. Additionally, H3K27me3 
and H4K20 were associated with gene repression. Afterwards, lysine demethylases 
(LSD1) are there to reverse such steady modifications at H3K4 and H3K9 [66, 67] 
as a co-repressor or co-activator respectively. Their nomenclature has already been 
changed from LSD1 to lysine demethylases (KDMs) [68]. In a study in lymphocytes 
from type 1 diabetic patients, as compared to controls increased H3K9me2 levels 
were reported to be correlated with immune and inflammatory pathways associated 
with diabetes and its complications including DN [69]. Such histone modifications 
at N-terminal are two key mechanisms that may alter development and progression 
of diabetes and its related complications; they are noteworthy as discussed below.
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In DN pathogenesis, expressions of a gene that are associated with DN are 
regulated by post-translational modifications of histone proteins, apart from DNA 
methylation. Smad2/3/4 (transcription factors) are activated by TGF-β and also 
team up with HATs and other chromatin remodeling factors. Alterations in DNA 
methylation and H3K9Ac at gene promoters were found to be associated with 
endothelial dysfunction in endothelial cells cultured in hyperglycemic conditions. 
Among various epigenetic mechanisms, methylation among core histone tails is 
considered to be the highly stable PTM that could be a key factor in the pathogen-
esis of various complications of diabetes. Previous studies have studied the role of 
histone modifications in cultured cells as well as animal model in the presence of 
TGF-β and high glucose environment, the two key factors in diabetes [70]. They 
reported an increased H3K9/14Ac at PAI-1 and p21 promoters near Smad/SP1 
binding sites. Cultured rat mesangial cells (RMCs), obstructed by TGF-β antibod-
ies, displayed increased levels of p21 and PAI-1 under hyperglycemic conditions. 
Also in glomeruli of diabetic animal model, increased expressions of PAI-1 and p21 
were found to be linked with increased promoter H3K9/14Ac. In the model of DN, 
TGF-β stimulated expressions of key fibrotic genes were found to be associated 
with enrichment of histone active chromatin marks (H3K4me1/2/3) and reduced 
repressive chromatin marks (H3K9me2/3) at their promoters [71]. Collectively, 
TGF-β plays as an intermediator in hyperglycemia induced histone modifications 
of promoters of key genes in mesangial cells leading to kidney damage. In glomeruli 
of diabetic mice, increased chromatin active marks along with decreased repres-
sive marks were observed at PAI-1 and receptor for AGE (RAGE) gene promoters 
as compared to control, which showed the regulation of histone modifications 
in kidney in the presence of hyperglycemia [72]. In addition, AT1R inhibitor 
decreased key indicators of DN and also reversed some of the epigenetic changes in 
diabetic mice including reduced H3K9/14Ac at PAI-1, RAGE and MCP-1 promoters 
in diabetic mesangial cells. In the animal models of DN, increased histone active 
marks (H3K4me2) and decreased repressive marks (H3K27me3) were observed 
to be associated with the expression of genes related to DN [73]. In the kidney of 
uninephrectomized db/db mice model, H3K4me2 levels were increased in associa-
tion with albuminuria, glomerular filtration rate and glomerular cell proliferation, 
which can be reversed by MCP-1/CCL2 antagonist [74]. In diabetic kidneys, HDAC 
inhibitor (Trichostatin A) has been observed to block the induction of TGF-β at 
essential fibrotic genes, both in vitro and in vivo. This implies major role of HDACs 
in TGF-β facilitated kidney fibrosis and ECM accumulation [75]. In another study, 
treatment of renal epithelial cells with Trichostatin A (TSA) resulted in downregu-
lated TGF-β mediated epithelial-to-mesenchymal transition (EMT) [75, 76]. Taken 
as a whole, these studies demonstrate the involvement of HDACs in renal injury 
via TGF-β.
Histone post-translational modifications have also been studied extensively in 
the context of DR. Increased oxidative stress and simultaneous decreased levels of 
retinal superoxide dismutase (SOD2) are the key features of DR. Increased histone 
repressive mark (H4K20me3) along with increased NF-κB p65 in association 
with decreased SOD2 mRNA levels and decreased activation marks (H3K4me1/2) 
at SOD2 promoters were observed in retinal endothelial cells cultured in high 
glucose. Acetylation of core histone protein on lysine residues is thought to opens 
up the DNA, thereby, increased availability for binding of transcription factors. 
Afterwards, activated proinflammatory transcription factors, for instance NF-κB, 
binds to particular sequence in DNA and activates and bind coactivators (like 
p300) having intrinsic HAT activity to the target promoters of target gene. These 
coactivator molecules then, regulate the expressions of target gene owing to their 
HAT activity [77]. Contrary to this, recruitment of HDACs results in compact 
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chromatin, coiled DNA and less accessibility for binding of transcription factors 
to DNA, thereby decreased expression of target gene. Hence, the balance between 
acetylation and deacetylation of histones regulates the transcription of the gene. 
Increased HDACs and decreased HATs along with decreased global histone acetyla-
tion activities were also found in diabetic retinal cells in the models of diabetic 
retinopathy [78]. However, reversal of hyperglycemic conditions did not able to 
restore changes in histone activities. This is in contrast to a study in diabetes where 
activation of histone acetylation was observed in retinal cells [79]. Pro-apoptotic 
enzyme, MMP-9, is also observed to be associated with epigenetic alterations in DR 
[80, 81]. Lysine of histone 3 was reported to be methylated by SUV39H1 resulted 
in H3k9me3 [82]. Another methyl transferase gene i.e., SUV39H2 is involved in the 
onset of disease, when methylates histone H3K9 results in the inception of DR [83]. 
Moreover under hyperglycemic conditions, recruitment of Set7 (HMT) at promoter 
region of NF-KB p65 unit was linked with its enhanced transcription [44]. Western 
blotting and mass spectrometry studies in diabetic rat model also confirmed the 
acetylation of several lysine residues on histones due to hyperglycemia leading to 
increased expressions of proinflammatory proteins in retina and associated  
with DR [79].
Oxidative stress also plays a central role in diabetic complications and has been 
shown to control histone acetylation or deacetylation in diabetic conditions. High 
blood glucose is known to increase ROS production, which further activates impor-
tant pathways that are required for the development of DR [84]. ROS is observed 
to inhibit acetylation of histones by increasing HDAC activity and decreasing HAT 
activity [85]. Hence, it was believed that there is involvement of ROS in regulating 
acetylation and deacetylation. Usually, oxidative stress was found to be increased 
in retina and capillary cells [86]. Thus, it is possible that diabetes via increased ROS 
production may regulates histone acetylation and deacetylation in retina. Ischemia 
and hypoxia are also known to promote the process of histone deacetylation [87] 
and hypoxia in diabetes is the leading cause for neovascularization in retina [88] 
which indicates the role of retinal hypoxia in diabetic retinopathy via stimulating 
retinal histone deacetylases. Thus, in hyperglycemia, epigenetic alterations may be 
involved at a larger level in modulating the expressions of various important genes 
in pathogenesis of DR.
Various researches on histone protein alterations may suggests that chromatin 
state is likely to be affected by multiple histone code modifications and hence, 
screening of various histone alterations at key genes promoters and/or bodies 
related to DN is crucial. The role of DNA methylation, histone code modifications 
and changes in epigenetic marks in response to various therapies is not well studied 
and would be of great concern to see whether these modifications could be altered 
in response to therapy. In future, more epigenome studies are required to elucidate 
the mechanisms of pathogenesis of DN that could help in developing better treat-
ment strategies for people suffering from this devastating complication.
c. Micro RNAs (miRNA):
Whole transcriptome studies (RNA-sequencing) have uncovered that major-
ity of the transcribed genome (into RNA) is non-coding part, apart from the 
coding mRNA [89]. Non-coding RNA refers to the RNA that does not code for 
any protein. These non-coding RNAs are also a part of epigenetic mechanisms 
that are of immense interest in the context of diabetic complications as they are 
observed to repress the expressions of target genes via regulating transcription 
and post-transcription mechanisms. Non-coding RNAs includes small non-coding 
RNAs (miRNAs approx. 20-22 bp long), circular RNAs (circRNAs) as well as long 
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non-coding RNAs (lncRNAs approx. 200 bp long). They are reported to control the 
expressions of important genes associated with diabetic complications. In contrast 
to miRNAs, few studies have observed the role of lncRNAs in DN [90, 91]. miRNAs 
are usually single stranded RNA of approximately 20–25 nucleotides long. They are 
well-known non-coding RNAs that involved in post-transcriptional regulation by 
means of either suppression of translation or degradation of mRNA transcript by 
binding 3’ UTR of target sequences [92, 93]. LncRNAs, instead, are usually longer 
(>200 bp) than miRNAs (20-22 bp). They function as scaffolds [94] and may regu-
late miRNA due to their antisense activity [95] and have tissue specific expressions 
[96]. Similar to mRNA, lncRNAs are formed due to transcription in the presence of 
RNA polymerase II and undergo splicing, although they are slightly polyadenylated 
[96]. LncRNAs also participate in modifications of epigenetic marks as they harbor 
histone methylation marks at H3k4 and H3K36 [97]. They are also reported to be 
involved in the development and progression of diabetic microvascular complica-
tions [98–101]. Recently circular RNAs, the next level of epigenetic regulation, are 
holding our interest in addition to lncRNAs as they are generated from mRNA via 
its back-splicing and later on both 5′ and 3′ spliced ends ligated together to form a 
circular structure. They regulate miRNAs, thereby regulating the expressions of 
miRNAs targetted genes. They also act as sponge for various miRNAs. Several cir-
cRNAs are observed to stimulate the pathogenesis of diabetes-related microvascular 
complications [102, 103].
On the other hand miRNAs, at first, were portrayed in C. elegans, a nematode, 
during early 1990s. Over 1000 miRNAs in human genome have been identified; 
lin-4 was the first described miRNA [104]. Various miRNAs are found in humans, 
algae, plants, animals and viruses [105]. miRNAs, unlike other small RNAs, are 
derived from the transcripts that themselves can rapidly fold back to form a 
hairpin-like structure. RNA polymerase II transcribed miRNA as primary tran-
script (pri-miRNA) in nucleus, where they are later spliced into precursor miRNAs 
(pre-miRNA) [106, 107] by the action of endonuclease complex. Exportin-5, a 
protein transport pre-miRNA into the cytoplasm from nucleus where they are 
further processed to mature miRNA duplex (~ 22 nucleotides) by the action of 
ribonucleases [107]. One strand of mature miRNAs is selected and loaded on 
RNA induced silencing complex (RISC) and other stand undergoes the process 
of degradation [106, 108]. This complex binds to their complementary sequence 
on mRNA for post-transcriptional suppression. Initially, lin-4 RNA was observed 
to have complementarity with conserved sites in mRNA of lin-14 [109] within 
untranslated (3’-UTR) site. But how to find their targets was the primary question 
in initial times. Algorithm tool, at first, identifies the perfect Watson-Crick pairing 
to 2–8 nucleotides of miRNAs starting from 5’region [110]. This 7 seven nucleotide 
sequence (at 5′-end) was termed as ‘miRNA seed’. This finding was clearly in agree-
ment with the earlier study which showed that 5′ end is the most conserved region 
in metazoan miRNAs [111]. Afterwards extending seed match with adding more 
base pairs to the miRNA continues in both directions, but stopping at discrepancies 
[110]. Therefore, the silencing effect of target gene by miRNA is via binding of 
seed sequence at miRNA with the complementary sequence at mRNA in 3’-UTR. 
miRNAs based therapies would have a better lead in that they can target multiple 
genes of a particular pathway or process [112]. Because, one miRNA can supress 
expression of many genes and subsequently one gene can also be targetted by more 
than one miRNAs. Another advantage is that these miRNAs can cross blood-retina 
barrier so as to get into the target tissue, which is the foremost obligation with this 
therapy. In past years, several studies have linked miRNAs with diabetic complica-
tions. Henceforth we have, now described the role of miRNAs in the pathogenesis of 
diabetes complications.
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Several miRNAs including miR-29, miR-192, miR-194, miR-200b/c, miR-204, 
miR-215, miR-216a, miR-217, miR-377 etc. have been found to be associated 
with DN. Characteristics of DN includes fibrosis, accumulation of extracellular 
matrix (ECM), podocyte dysfunction and proteinuria [113, 114]. TGF-β has been 
implicated in the pathogenesis of DN and is found to be upregulated during the 
progression of DN, which in turn, induce fibrotic events, kidney deterioration 
and dysfunction [114]. TGF-β has shown to upregulate several miRNAs including 
miR-192, miR-216a, miR-217 in mesangial cells as well as in kidneys of diabetic 
mouse models as compared to control group [115–117]. ZEB2, a translation repres-
sor that supress fibrotic gene collagen type 1 Alpha 2 (Col1a2), was observed to get 
suppressed by miR-192, thus, resulted in an increased expression of Col1a2 gene 
and contribute to matrix accumulation and kidney fibrosis in DN model [115]. In 
diabetic mice, increased expressions of p53, TGF-β and miR-192 was reported in 
renal cortex and was found to be associated with augmented fibrosis and glomeru-
lar expansion as compared to control. Moreover, knockout of miR-192 gene resulted 
in decreased markers of DN. However, conflicting reports to these results are also 
described. One of such reports observed that TGF-β decreased the expression of 
miR-192 in cultured proximal tubule cells and concluded that decreased miR-192 
levels are associated with increased fibrogenesis in PTCs [118]. Another study also 
showed that kidney fibrosis was associated with the loss of miR-192 [119]. These 
contradictory studies showed that the interconnection between DN and miR-192 
is much more complicated than it seems. Also, a decreased expression of miR-21 
was found in DN and albuminuria was decreased in diabetic mice due to ectopic 
expression of miR-21 [120]. miR-377 expression was found to be upregulated in 
DN [121]. It actually alters the levels of MnSOD and PAK1, which in turn, resulted 
in augmented fibronectin expression in mesangial cells in streptozotocin (STZ)-
induced diabetic model, thus contributing to DN progression indirectly. TGF-β 
induced miR-216a expression has been shown to increased collagen (Col1a2) 
expression [116] and subsequently participates in the fibrogenesis in proximal 
tubular cells (PTCs) [122]. Another important contributor to DN is VEGF and 
treatment with anti-VEGF showed to improve kidney functions in diabetic animal 
model [123]. Earlier miRNA-93 was considered as ‘signature miRNA’ in both in vivo 
as well as in vitro hyperglycemic environment [124]. Long et al. also demonstrated 
that increased expression of miR-93 resulted in reduced high glucose-stimulated 
VEGF-A levels via downregulation of the host MCM7 gene promoter.
Earlier studies have also reported the role of miRNAs in diabetic retinopathy. 
Neovascularization is the hallmark of DR and several studies have confirmed the 
importance of miRNAs in neovascularization regulation in retina [125]. Microarray 
studies recognized increased (miR-146, miR-106a, miR-181, miR-199a, miR-
214, miR-424 and miR-451) as well as decreased expressions of various miRNAs 
(miR-31, miR-150, miR-184) in model of ischemic retinopathy [126]. In retina and 
retinal endothelial cells (RECs), increased miRNAs corresponding to NF-κB, p53 
and VEGF were identified reflecting pathological changes of early DR by means of 
functional analysis, thus, revealing the role of miRNA in pathogenesis of DR [127]. 
In diabetes, downregulated miR-200b was detected in retina of diabetic rat model 
with simultaneous elevated levels of VEGF mRNA and protein. In addition, in vitro 
miR-200b antagonist transfection resulted in elevated VEGF expression [128]. 
This demonstrates VEGF to be the direct target of miR-200b. During early stage 
of diabetes, miR-29 shown to be anti-apoptotic for retinal ganglion cells (RGCs) 
and inner nuclear layer (INL) cells through pro-apoptotic RNA dependent (PKR) 
signaling pathway [129].
Therefore, this chapter has enlightened the role and contribution of epigenetic 
mechanisms in the pathogenesis of two major diabetic vascular complications i.e., 
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DN and DR. Together all, it indicates the important connection of miRNAs with 
microvascular complications of diabetes; hence, it would be worth to explore the 
role of these alterations in the pathophysiology of DN as well as DR. As reviewed in 
this chapter, methylation in DNA, histone tail alterations and variable expressions 
of miRNAs are found to be altered in hyperglycemic environment either upregu-
lated or downregulated affecting directly or indirectly. Current treatment for DN 
and DR is not able to stop the progression of these devastating complications, 
henceforth, focusing treatment approaches via targeting epigenetic alterations 
alone or in combination with conventional therapy could provide a new approach to 
combat or retard the progression of these diabetic complications. However, the fact 
that a particular miRNA can have multiple targets made it difficult and challeng-
ing with few limitations, still it will increase our understanding about the disease 
pathophysiology.
4. Targeting diabetic complications via targeting epigenetic marks
Heritable epigenetic alterations are the results of interactions between envi-
ronmental (momentary) and genetic (long-standing) components and thus, may 
play a decisive role in the pathophysiology of diabetic complications. They are able 
to alter the gene expression, thereby, gene function, the underline mechanism 
in the pathogenesis of vascular complications of diabetes. Reversible attribute 
of epigenetic marks provides immense opportunity of developing restorative 
interventions for treating patients with these complications. Till date, some of 
the drugs targeting epigenetic marks are already being clinically used for cancer 
therapy including HDAC inhibitors [130] and DNA methylation inhibitors [131, 
132]. However, preclinical studies targeting histone as well as DNA methylation 
are still in progress [133–135]. Metformin, the current line of drug for treating 
hyperglycemia, upregulates sirtuin 1 (SIRT1) expression along with downregulat-
ing NF-κB expression [136], SIRT1 has been shown to possess NAD+-dependent 
protein deacetylase activity [137]. In glomerular mesangial cells, SIRT 1 induces 
antioxidant genes and simultaneously downregulates TGF-β1 and the expression 
of AGEs-induced fibronectin [138]. In diabetic mice glomeruli, BF175, a SIRT1 
agonist, ameliorates hyperglycemia-induced podocyte loss, proving the protective 
role of SIRT1 against diabetes-induced kidney damage [139]. Recently, angiotensin 
II (Ang II) of RAAS has been reported to induce the expressions of few non-coding 
RNAs including miRNAs [140] and lncRNAs [141] as well. Enhancers, the elements 
that affect transcription of genes and are associated with specific histone modifica-
tions [142], when blocked by JQ1, a Bromodomain (an epigenetic reader) inhibitor, 
also obstructs enhancer functions along with attenuation of Ang II-mediated 
hypertension and inflammation in vivo in vascular smooth muscle cells (VSMCs) 
[143], hence, strongly supporting the importance of targeting enhancers in Ang 
II-mediated actions for treating vascular complications. This, in turn, could reveal 
evidence directing new therapeutic interventions for treatment of diabetic vascular 
complications. In addition, the modified inhibitor of miR-192 i.e., Locked nucleic 
acid (LNA) not only downregulates key fibrotic markers of kidney damage but also 
shown to reduce proteinuria in diabetic mice [144], favoring miRNAs based thera-
peutic interventions for DN. Several studies have also reported the amelioration of 
kidney-injury parameters via targeting miR-21 [145–147] implying that its inhibi-
tion could be a promising therapeutic intervention in DN. Recently with the use of 
latest and advanced approach of genome editing i.e., CRISPR-Cas9, locus-specific 
changes in epigenetic alterations could be generated owing to the fusion of Cas9 
proteins with various DNMTs or TETs or histone modification proteins [148–150], 
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thus, reversing the epigenetic marks of important genes involved in the pathogen-
esis of s disease. Despite extensive ongoing research, more detailed epigenetics-
targeted approach is required to combat diabetic microvascular complications.
5. Conclusion
In conclusion, discovering specific role and targeting pathways related to 
epigenetic alterations for the development of therapeutic interventions in T2DM 
patients with microvascular complications could be promising. Moreover, this will 
certainly be helpful in increasing our knowledge and developing tools for better 
and early diagnosis and subsequent more effective treatment of these distressing 
complications in clinical practice.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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